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Tuberculosis infection is a serious human health threat and the early 21st century has seen
a  remarkable increase in global tuberculosis activity. The pathogen responsible for tuber-
culosis is Mycobacterium tuberculosis, which adopts diverse strategies in order to survive in
a  variety of host lesions. These survival mechanisms make the pathogen resistant to cur-
rently  available drugs, a major contributing factor in the failure to control the spread of
tuberculosis. Multiple drugs are available for clinical use and several potential compounds
are  being screened, synthesized, or evaluated in preclinical or clinical studies. Lasting and
effective  achievements in the development of anti-tuberculosis drugs will depend largely on
the proper understanding of the complex interactions between the pathogen and its human
host.  Ample evidence exists to explain the characteristics of tuberculosis. In this study,we  highlighted the challenges for the development of novel drugs with potent bacterio-
static  or bactericidal activity, which reduce the minimum time required to cure tuberculosis
infection.
agement  strategies for TB and the inadequate effectiveness of
public  health systems, mainly in underdeveloped countries.
© 2013 Elsevier Editora Ltda.      Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
The pathogen responsible for tuberculosis (TB) infection,
Mycobacterium tuberculosis, was  ﬁrst identiﬁed by Robert Koch
in  1882. However, the global TB epidemic remains undimin-
ished  and is expected to reach 9,8 million new cases in 2010,
more  cases than in any previous year in history. About 80% of
these  new TB cases will be found in the 20–25 highest-burden
countries, with more  than one-third in India and China. A
review  of the TB cases reported by 134 countries between 1998
and  2007 found that only 35 had per capita rates of decline
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Este é um artigo Open Access sob a licença exceeding 5% per year.1 However, surveillance and mathemat-
ical  modeling suggests that the total TB incidence per capita
is  falling at an estimated 1% per year, a ﬁnding that indicates
that  the global incidence rate will decrease by 2015. However,
the  world’s population is growing at about 2% per year, and
thus  the total number of new TB cases remains on the rise.2
This ﬁnding reveals the relative failure of the existing man-In  spite of the availability of anti-TB drugs developed over the
last  ﬁve decades, one-third of the world’s population retains a
de CC BY-NC-ND
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Shorten treatment time Treat MDR-TB and XDR-TB
Reducing pill burden
Lower dosing frequencyDrug-drug interactions
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heterogenous populations
New class of chemicals with
broadmechanism of action
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as well as child friendly
Enhance bioavailability with longer
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Fig. 1 – A schematic representation for new tuberculosis (TB) drugs. The desired proﬁle of each product is enlightened by
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ormant or latent form of M. tuberculosis. These populations
re  generally asymptomatic but remain at lifelong risk of
isease  reactivation and represent a high risk factor for the
pread  of the disease (Fig. 1).
Currently, the TB epidemic is further exacerbated by the
xistence  of multidrug resistant-TB (MDR-TB) and extremely
rug  resistant-TB (XDR-TB) strains and declining treatment
ptions as least three effective drugs are required to be used
n  combination in order to successfully treat the disease while
reventing  the development of further drug resistance.3 The
ast  drug therapy discovered and approved, which employs
 new mechanism of action for treatment of TB, was com-
ination  dosing using isoniazid (INH) and rifampicin (RIF).
owever,  MDR-TB is resistant to INH and RIF. Cases of MDR-
B  and XDR-TB result from either primary infection with
 drug-resistant bacteria strain or non-optimal treatment
urations or regimens. In spite of the introduction through-
ut  the world many  years ago of concomitant chemicals
or  use in TB treatment, lower cure rates for MDR-TB have
een  observed, ranging from 50 to 70%.4 XDR-TB is resis-
ant  to INH and RIF, all ﬂuoroquinolones, and at least one of
he  second-line anti-TB injectable drugs including amikacin,
anamycin and/or capreomycin. These types of resistance
B  infections produce very high mortality rates.3 Further-
ore,  the occurrence of drug–drug interactions excludes the
o-administration of some existing TB drugs with other medi-
ations  used in chronic diseases.5 Multiple effective therapies
eed  to be developed that produce multiple functions such
s  shortening of treatment time, efﬁcacy against MDR-TB and
DR-TB  strains, simpler treatment regimens including lower
osing  frequencies, and therapies that can be co-administered
ith medications used in other chronic diseases. The chal-
enge  of meeting the spectrum of expectations for this desired
arget  product proﬁle complicates drug discovery efforts as
any  of the forthcoming compounds are either derivatives
f  presently used compounds or modulate the same cellu-
ar  processes as drugs currently in use.5,6 In addition, theeatures.
analogues and derivatives in development are far from trans-
lation  into the clinic, may  be subject to cross-resistance, and
may  be hampered by the unfavorable economics surrounding
TB  drug development and lack of proper policy incentives.
The  aim of this study was  to determine whether or not
there  are a sufﬁcient number of promising compounds in the
TB  pipeline necessary in order to achieve global control of this
epidemic.  We  presented a mechanism of action against TB
infection,  provided a perspective with the goal of improving
the  focus of discovery and development efforts, and identiﬁed
the  underlying knowledge gaps and scientiﬁc obstacles in TB
drug  development.
Drug  resistance  mechanisms  in  Mycobacterium
tuberculosis
The existing situation surrounding the growing drug-resistant
TB  patient population is signiﬁcantly disquieting and repre-
sents  a signiﬁcant weakness in the ability to control disease on
a global scale.5,6 Any viral infection causing human immune
system deﬁciency can reactivate the TB infection5 and gen-
erate  the potential of producing new TB cases. In recent
reports, the percentage of MDR cases demonstrating resis-
tance  to various classes of antibiotics ranged from 0 to 22.3%.6
Around 40.000 cases of XDR-TB are projected to emerge world-
wide  each year.5,7 It is of utmost importance to ﬁgure out
the  mechanisms through which the mycobacterial cells resist
anti-tuberculosis drugs. Understanding the mechanism will
enable  the design of new anti-tuberculosis drugs as well as
methods  for interfering with the expression of such drug
resistance.7
The resistance to TB drugs appeared very soon after the
introduction of the ﬁrst drug, streptomycin. Chromosomal
mutations occurring at a frequency of 10−6 to 10−8 mycobacte-
rial replications enable the development of genetic resistance
to  an antibacterial drug.5 The advantage of using a multidrug
 i s . 276  b r a z j i n f e c t d
regimen lies in the fact that the chromosomal loci responsible
for  resistance to various drugs are not linked. Thus, the pos-
sibility  of developing resistance to three drugs administered
simultaneously becomes 10−18 to 10−20, an outcome whose
probability is extremely low or almost negligible.8 Enormous
efforts  have been made to identify the molecular basis of drug
action  and resistance in the TB pathogen. The drug action and
the  bacterial resistance mechanism of a few commonly used
drugs  have been brieﬂy summarized to highlight the need
for  novel drug design that could reduce treatment time and
avoid  the occurrence of drug resistance in the treatment of TB
infections.
Resistance  to  anti-TB  drugs
Isoniazid  (INH)
Since its introduction as an anti-TB drug in 1951, INH has
been  the most widely used treatment for TB and its latent
infections.9,10 INH penetrates into the cell as a pro-drug acti-
vated  by katG, the gene encoding catalase-peroxidase. The
peroxidase  activity of this enzyme is essential in activating
INH  and enabling its interactions with various toxic reactive
species  in the bacterial cell.11 The reactive species usually con-
sist  of oxides, hydroxyl radicals, and organic moieties that
deteriorate components of the cell wall which results in the
loss  of cellular integrity, and ﬁnally, bacterial death.12 The
resistance frequency of 105,6 for INH is much  higher than
that  for most anti-tuberculosis drugs.13 InhA enzyme (enoyl-
acyl  carrier protein reductase), involved in the elongation of
fatty  acids in mycolic acid synthesis, is considered the pri-
mary  target of INH inhibition.14 The replacement of an amino
acid  in the NADH binding site of Inh A apparently results
in  INH resistance, preventing the inhibition of mycolic acid
biosynthesis. Various genetic mutations have been observed
to  occur usually between codons 138 and 328; the Ser315Thr
mutation is most frequent and found in about 40% of all INH-
resistant  strains.15–17 The mutation at Ser315Thr results in
an  enzyme lacking the ability to activate INH, but preserves
approximately 50% of its catalase-peroxidase activity.18 Thus,
the  modiﬁed catalase-peroxidase offers high-level resistance
to  INH while maintaining a high level of oxidative protection
sufﬁcient to facilitate the organism in sustaining its detoxify-
ing  activity against host antibacterial free radicals.
Rifampicin  (RIF)
Rifampin, rifapentine, and rifabutin have been commonly
used  as ﬁrst-line therapies in combination with other drugs
for  the treatment of TB infections. The use of RIF in combina-
tion  with PZA/INH led to the establishment of short therapy
courses,  which reduced routine TB treatment from 1 year to
6  months. RIF is believed to inhibit bacterial DNA-dependent
RNA polymerase. RNA polymerase is composed of four differ-
ent  subunits (, , ′, and ), and the genetic loci coding for
these subunits include the rpoA, rpoB, rpoC, and rpoD genes,
respectively. RMP  interferes with RNA synthesis by binding
to  the  subunit of the RNA polymerase, hindering transcrip-
tion  and thereby killing the organism. Resistance to RIF arises 0 1 3;1 7(1):74–81
due  to missense mutations in the gene. In M.  tuberculosis,
resistance to RIF occurs at a frequency of 10−7 to 10−8,5 The
resistance in RIF develops due to mutations in a distinct,
81-base-pair (bp) (27-codon) central region of the gene that
encodes  the -subunit of RNA polymerase.19 About 96% of
all  mutations are found in the 81-bp core region of the gene
between  codons 507 and 533, with the most common changes
occurring  in codons Ser531Leu, His526Tyr, and Asp516Val.20
Pyrazinamide  (PZA)
PZA is a vital ﬁrst-line drug for the treatment of tuberculo-
sis.  PZA has an excellent sterilizing effect on semidormant
tubercle bacilli. By killing semidormant bacilli in an acidic
environment, PZA, along with INH and RIF, forms the cor-
nerstone  of modern TB treatment therapy. PZA has played
an  important role in reducing the duration of TB treat-
ment from the previous 9–12 months to the current 6
months.21 PZA is a prodrug that is converted to its active
form pyrazinoic acid (POA) by the mycobacterial enzyme
pyrazinamidase/nicotinamidase. PZA, produced intracellu-
larly,  diffuses into the tuberculosis pathogen in a passive
manner, and is converted into POA by pyrazinamidase within
the  cell. The inefﬁcient efﬂux system of the mycobacterial cell
enables massive accumulation of POA in the bacterial cyto-
plasm,  leading to disruption of the membrane potential.22,23
The exact mechanism of PZA resistance remains unknown.
However, it is known that PZA-resistant bacterial strains
usually  lose their pyrazinamidase activity.24 Cloning and
sequencing studies of the gene that encodes pyrazinamidase
revealed that 72–97% of all PZA-resistant clinically isolated
specimens carry a mutation either in the structural gene or
in  the putative promoter region of the gene.25
Ethambutol  (EMB)
EMB is a ﬁrst-line drug that is used in combination with
INH,  RIF, and PZA in order to prevent the emergence of
drug  resistance speciﬁc to mycobacterium. EMB  is an active
bacteriostatic agent for bacilli that are growing but has
no  effect on non-replicating bacilli. EMB  interferes with
the  mycobacterial cell wall through a synthetic mechanism
and  inhibits arabinosyl-transferase, which is involved in cell
wall  biosynthesis.26 Encoded by arabinosyl-transferase and
involved  in the synthesis of arabinogalactan, arabinosyl-
transferase has been proposed as the target of EMB  action
within  the tuberculosis organism.27 Studies have shown that
resistance  to EMB is due to random spontaneous genetic
mutations occurring at a rate of approximately 1 in 107
organisms; mutations most commonly result in increased
production of the enzyme arabinosyl-transferase, which over-
whelms  the inhibitory effects of EMB.  Studies have identiﬁed
ﬁve  mutations in codon 306 including ATG-GTG, ATG-CTG,
ATG-ATA, ATG-ATC, and ATG-ATT that result in three different
amino  acid substitutions (Val, Leu, and Ile) in EMB-resistant
strains.28,29 These ﬁve mutations are associated with 70–90%
of  all EMB resistant isolates.29
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urrent  challenges  in  the  TB  treatment
he current anti-TB drugs, discovered primarily in the 1950s
o  1970s, were  developed through a series of clinical trials
hat  extended into the 1980s.30 The subsequent 30 years,
ntil  approximately 2000, represented a fallow period in TB
rug  research and development, a void contributing greatly to
he signiﬁcant challenges currently faced by the community
f  drug developers focused on markedly improving treat-
ents  for active MDR-TB and XDR-TB. At present, MDR-TB
s  treated using a combination of different drugs with ther-
pies  lasting 18–24 months, with only four of these drugs
eveloped for the purpose of treating TB.31 Suboptimal ther-
py  leads to almost 30% of MDR-TB patients experiencing
reatment failure.32 The treatment options for XDR-TB are
ery  limited because XDR-TB bacilli are resistant, not only to
NH  and RIF, but also to ﬂuoroquinolones including injectable
rugs  such as aminoglycosides. In addition, there are seri-
us  side effects observed with most MDR-TB and XDR-TB
rugs,  including nephrotoxicity and ototoxicity with the use of
minoglycosides, hepatotoxicity with the use of ethionamide,
nd  dysglycemia with the use of gatiﬂoxacin.33
The vast majority of TB cases and deaths occur in poor
ountries and about one in four of the deaths occur among
IV-positive people. It has been reported that 9,4 million
atients diagnosed with TB in 2009 (11–13%) were also HIV
ositive  with approximately 80% of these morbidities con-
ned  to the African region.34 This is due to limited health
are  access as well as diminished compliance with therapeu-
ic  regimens associated with increased pill burden, drug–drug
nteractions, and overlapping toxic side effects. The primary
nteraction between HIV and anti-TB treatment agents is RIF-
nduced  overexpression of the hepatic cytochrome (CYP P450)
xidase  system.35 Studies have shown that CYP increased the
harmacokinetic rate and decreased the efﬁcacy of several
oncomitant medications including HIV protease inhibitors.36
t is noted that with the use of CYP450 inhibitors, such as
itonavir,  normal trench levels of various classes of protease
nhibitors cannot be regained. Accordingly, they have been
hown  to compete with rifampicin in intracellular phosphor-
lation.  Thus, these drugs should not be co-administered.
owever, the presence of ritonavir in a protease cock-
ail  increases the serum concentration of rifabutin, thereby
ncreasing its accompanying toxicity.37 Multiple drug interac-
ion  studies are few for most second-line TB drugs such as
thionamide, cycloserine, kanamycin, amikacin, capreomycin
nd  para-amino salicylate, which have been in use since the
ast  decade for treating HIV patients with MDR- or XDR-TB
train  co-infections.38 Therefore, speciﬁc active case-ﬁnding
trategies are needed to target HIV-infected individuals as well
s the interaction of anti-retrovirals with currently available
econd-line TB drugs, as well as those currently in clinical
evelopment.
Like  HIV, diabetes is also associated with the suppres-
ion of cell-mediated immunity and is known to increase the
39isk  of developing active TB by three-fold. Studies in 2000
evealed  that approximately 20% of smear-positive TB cases
ere  attributed to concurrent diabetes in India.40 In the mean-
ime,  if the projected rise from 25 million diabetes cases in 1 3;1  7(1):74–81  77
2000  to 80 million in 2030 comes to fruition, and the risk ratio
remains  the same, then 42% of smear-positive TB cases in
India  will be attributable to diabetes by 2030. Each TB case
caused  by diabetes would also potentially lead to the infec-
tion  of other people, adding to the overall TB burden in the
community.41 The biological basis for the limited response
of  diabetics to anti-TB agents and for their increased risk of
developing  MDR-TB is poorly understood. But, it is believed
that  cell-mediated immunity is suppressed in diabetes and
fosters  higher TB infection rates.
Future  clinical  TB  drugs  to  overcome  drug
resistance
Development of drugs for the treatment of TB and other
epidemic diseases has been lacking for decades. The conven-
tional  approach to TB drug development requires substituting
each  approved drug in the current multi-drug regimen, but
only  after the new drug has been approved for treatment as
a  single agent. TB control initiative program for the testing of
new  compounds simultaneously could drastically shorten the
development  timeline, but ethical implications should be con-
sidered in the identiﬁcation of a practical way  to implement
such  clinical trial designs.5,6
Adenosine  triphosphate  (ATP)  synthase  inhibitors
The selection of new TB drug targets has been determined
mainly by accessibility to the genome sequence of the TB
pathogen.  But studies dealing with the invention of new
drugs  have shown that genome-derived and target-based
approaches generally have modest therapeutic effects in the
area  of antibacterials.42 Studies have also shown that chang-
ing  the selection approach from single-enzyme targets to the
whole  bacterial cell level greatly improves the effects of TB
drugs.  However, the whole-cell screening approach is hin-
dered  by a lack of understanding of the mechanism of action
as  well as identiﬁcation of the relevant ligands for internal
infections.43 Current achievements utilizing the whole-cell
approach are highlighted by the identiﬁcation of new TB drug
agents  such as TMC207, a diarylquinoline that inhibits ATP
synthesis,  and BTZ043, a benzothiazine that blocks arabi-
nan  synthesis.44,45 TMC207 (R207910 or the ‘J’ compound) is
active  against drug-sensitive and drug-resistant M. tuberculo-
sis  isolates.46,47 Along with bactericidal characteristic against
dormant (non-replicating) tubercle bacilli, it also has the
potential  to minimize the treatment duration.48 TMC207 has
shown  same inhibitory effects in murine model of tubercu-
losis  likely shown by isoniazid, rifampin, and pyrazinamide
in  a combination. However, a signiﬁcant increase in the rate
of  bacilli clearance was  reported by using TMC207 along
with  triple-drug regimen and the synergistic interaction with
pyrazinamide.49 Moreover, it has been reported that TMC207
in  case of murine model of drug-sensitive enhances the effec-
tiveness  of second-line drug combination.50 TMC207 has also
been  evaluated in phase II dose ranging trial conducted for
7  days in patients with drug-susceptible tuberculosis. The
results  reveal that only at the highest dose (400 mg)  clini-
cally  relevant bactericidal activity was achieved with a delay in
 i s . 278  b r a z j i n f e c t d
onset of response. This treatment was  associated with accept-
able  adverse-events.51 Additionally, controlled trial having
consisting of an (8 weeks) followed by a separate proof-of-
efﬁcacy stage (24 weeks), was  conducted to evaluate TMC207
efﬁcacy  in patients with newly diagnosed, smear-positive
pulmonary infection caused by multidrug-resistant M. tuber-
culosis.  TMC207 reduced the time interval to conversion to a
negative  sputum culture.51 These examples demonstrate that
multi-dimensional signaling pathway inhibition can be used
as  the basis for the identiﬁcation of new TB treatment scaf-
folds.
Protein  synthesis  inhibitors
Remodeling of present regimens is also a viable strategy for
fueling  momentum in the antibiotic development pipeline and
discovering  new treatment scaffolds for use against resistant
bacterial  strains. Different members of each antibiotic class
share  a common core structure, and upon synthetic modiﬁca-
tion,  the core of the antibiotic is left intact but its functional
groups are rearranged to potentiate the drug’s activity.
The  tailored forms of oxazolidinones (linezolid against
Gram-positive infections) have provided a platform for new
structures  such as PNU-100480 and AZD-5847, which have
been  found to enhance antibiotic activity.44 For the very
ﬁrst  time, 4-amino-1,2-oxazolidin-3-one (cycloserine), a new
class  of antibacterial agent, was  used. Cycloserine is a broad-
spectrum  antibiotic that has been used as a second-line
antituberculosis drug since 1955.52,53 In the modern era when
several  bacterial strains are becoming resistant against antibi-
otics,  linezolid (Zyvox) is the only agent approved by Food
and  Drug Administration (FDA) in the class and released in
2000  by Upjohn for the treatment of nosocomial pneumonia
and  skin and soft tissue infections caused by Gram-positive
bacteria.52 Against MDR-TB, linezolid was  the ﬁrst oxazolidi-
none  that has been used off-label, However, its long-term use
has  not been prescribed because of certain side effects asso-
ciated  with its continuous use, such as thrombocytopenia,
anemia, and peripheral and optic neuropathy.54 For M. tubercu-
losis,  minimum inhibitory concentration (MIC) is in the range
of  0,125–1,0 g/mL; because of its severe side effects it was
replaced by PNU-100480 (Sutezolid), an analogue of linezolid
developed by Pizer with similar MICs for M.  tuberculosis, for
better  in vivo activity and less toxicity.52,55,56 In a compari-
son study of the murine model of TB, PNU-100480 has shown
more  potent bactericidal activity compared with linezolid,
even  at lower drug exposures.44 Additionally, the introduction
of  PNU-100480 enhanced the bactericidal activities of regi-
mens  containing some ﬁrst-line drugs to certain folds, giving
a  clue that it may  be effective at minimizing the treatment
duration for drug-susceptible TB by 1–2 months.57 An earlier
study  investigated its safety, tolerability, pharmacokinetics,
and pharmacodynamics in humans by giving different doses,
i.e.,  100, 300, or 600 mg  twice daily or 1200 mg  once daily for
14  days, or 600 mg  twice daily for 28 days, to which PZA was
added  on days 27 and 28. A sixth cohort was  given linezolid
at  300 mg  daily for 4 days. None of the doses given showed
any  lethal effect and were  well tolerated.58 Cmax level was  0,94
or  2,01 g/mL, and half-life was  2,92 or 3,38 h, respectively, in
healthy  volunteers receiving twice-daily 600 mg  or once-daily 0 1 3;1 7(1):74–81
1200  mg  of PNU. Trough concentrations were  maintained at
or  above the MIC. An EBA analysis suggests daily testing of
600  mg  and 1200 mg  for 14 days. AZD-5847 (posizolid) is a lead-
containing  compound that is used to cure TB by AstraZeneca.
It  possesses an MIC analogous to that of linezolid and PNU-
100480  for curing M.  tuberculosis, and has shown profound
effect in mouse model experiment of TB.53 At 600 mg  oral dos-
ing,  Cmax is 2,60 g/mL in fasting subjects and 5,66 g/mL in
fed  subjects, with a half-life close to 8 h but it has caused
nausea in the test organism.53 A daily oral dose of 800, 1600
and  2400 mg for 14 days in healthy volunteers was well tol-
erated,  and has caused an increased Cmax up to 10 g/mL;
however, the increase was  not in proportion to the dose.53
Similarly, cephalosporins such as cefaclor and ceftazidime are
more impervious to destruction by the resistance enzyme -
lactamase, and enter the bacterial membrane more  efﬁciently.
Furthermore, new -lactamases can cleave third-generation
cephalosporins. Thus, fourth-generation molecules such as
cefepime were developed that are less susceptible to cleavage
by  -lactamase.45 Cephalosporins and other semi-synthetic
antibiotics harbor 64% of the new chemical scaffolds that were
ﬁled  between 1981 and 2005.59
Nitromidazole  (PA-824),  Delaminid  (OPC  67683)
PA-824 is a prodrug derived from metronidazole that has
shown  strong activity against anaerobic bacteria and proto-
zoa  (trichomoniasis, amoebiasis). PA-824 has demonstrated
signiﬁcant sterilizing and anti-tuberculosis activity, with an
MIC90  of 0,125 g/mL against both drug-resistant and non-
drug-resistant strains of M.  tuberculosis.60 It is bactericidal
against actively replicating and latent (non-replicating or
slowly  replicating) TB bacteria. Its bactericidal mechanism
against replicating aerobic species involves the inhibition of
synthesis  of certain proteins and cell wall lipid components
required for the survival and replication of bacterial species.
The  latent bacteria are killed by releasing nitric oxide gas dur-
ing  enzymatic nitro-reduction that poisons the respiratory
machinery.61 In murine models of TB, PA-824 demonstrated
bactericidal activity not only during initial phase but also in
the  continuation phase where it killed the bacteria that had
survived  for initial two months.62 The individual administra-
tion of PA-824 has shown bactericidal activities comparable
to  that of moxiﬂoxacin and isoniazid.63 The evaluation of PA-
824  in combined therapies with ﬁrst-line drugs to shorten the
treatment  time produced encouraging results. Its daily intake
in  combination with moxiﬂoxacin and PZA has contributed
to  an impressive sterilizing regimen, signifying the potential
to  shorten the treatment time.64 A study compiled by sub-
stituting isoniazid with PA-824 remarkably lower lungs CFU
after  2 months treatment as well as led to a rapid culture-
negative conversion when compared ﬁrst-line combination of
rifampin,  INH and PZA.65 Its substitution with rifampin in
ﬁrst-line  drug during intensive phase therapy is suggested
to  drastically reduce the treatment of multidrug-resistant
66tuberculosis. Different amounts of oral doses of PA-824 were
given  to TB patients in comparison to the control (standard
ﬁrst-line TB treatments). The results conﬁrmed promising
bactericidal activities of PA-824, signifying that soon it will
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e included in regimen for quick and effective treatment of
rug-susceptible and drug-resistant TB.67
NA  gyrase  inhibitors
luoroquinolones are a group of antimicrobials that kill M.
uberculosis  via double-stranded breaks in DNA, by binding to
NA gyrase. DNA gyrase consists of two A and two B subunits
ncoded by the gyrase A (gyrA) and gyrase B (gyrB) genes,
espectively.68 Previously drugs such as oﬂoxacin and levo-
oxacin  were  in use rather than the nalidixic acid derivatives
oxiﬂoxacin and gatiﬂoxacin, which are being developed cur-
ently for DS-TB. The gatiﬂoxacin by the Oﬂotub Consortium
NCT00216385) and moxiﬂoxacin by Bayer and the TB Alliance
NCT00864383) have been evaluated in Phase III trial, substi-
uted  with the ﬁrst-line regimen for ethambutol (gatiﬂoxacin,
oxiﬂoxacin) and isoniazid (moxiﬂoxacin) to shorten treat-
ent  of DS-TB.69 Several studies have shown the potential of
oxiﬂoxacin  and gatiﬂoxacin in vitro and in mouse models
f  TB70,71 as well as in humans.72,69 Additionally, the poten-
ial toxicities of these drugs are mostly group related, but
mong  them, gatiﬂoxacin has been reported to disturb glucose
etabolic  state in diabetic and aged individuals.73 In contrast,
his  type of drawback was  not associated with moxiﬂoxacin
reatment.74 Studies have also shown the reduced drug–drug
nteraction of gatiﬂoxacin and moxiﬂoxacin because these
rugs  are not strong inhibitors or inducers of the CYP enzyme
ystem  and also not metabolized to a great extent.75 RIF is
rst  line TB drug, which reduced approximately 30% plasma
oncentrations of moxiﬂoxacin but according to the phar-
acokinetic and dynamic condition of moxiﬂoxacin, RIF
nduce  glucuronidation or sulphation which reduced moxi-
oxacin  plasma level in 18 out of 19 patients.76,77 We hope
hat  the Phase III trials will elaborate the safety and efﬁ-
acy  of a 4-month, ﬂuoroquinolone-based treatment for drug
usceptible-TB, which could be translated to the clinic for the
reatment  of TB by 2015.
onclusion
n this report we provided examples of persistent TB trans-
ission  and of enhanced susceptibility of large populations
o  infection and disease. It is clear that all currently approved
B  drugs are facing a certain level of resistance governed by
peciﬁc  genetic mutations in the disease-causing Mycobac-
erium.  Long-term use of a speciﬁc drug results in the loss
f  its efﬁciency with increasing levels of bacterial resistance.
herefore, the right drug should be taken at the right time
n  order to avoid development of severe bacterial resistance
roblems. This study also highlighted some promising bacte-
icidal  agents for quick prevention and effective treatment of
rug-susceptible and drug-resistant TB.
Another suggestion by WHO  is to change the drug dos-
ng  at regular intervals within a prescribed format.78 Besides
hese  approaches, it is important to develop novel drugs that
void  the manifestation of drug resistance in bacterial cells.
e  conclude that control programs  have been less effective
han  expected in reducing the occurrence of TB transmission,
ainly because patients are not diagnosed and cured quickly
1 1 3;1  7(1):74–81  79
enough.  We  do hope that enhancing features of antibiotics will
help in developing improved tools for TB control. These TB
control  efforts will need to be reinforced and redoubled if TB
is  to be eliminated as a global public health crisis. The priority
now  should be to maintain the basic principles of treatment
using  chemotherapy such as gatiﬂoxacin and moxiﬂoxacin but
implement these efforts with greater vigor.
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